2-[methyl-(2-pyridin-2-yl-ethyl)-amino]-ethanol | 33932-13-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[methyl-(2-pyridin-2-yl-ethyl)-amino]-ethanol
• 英文别名: 2-[Methyl(2-pyridin-2-ylethyl)amino]ethanol
• CAS: 33932-13-7
• 化学式: C₁₀H₁₆N₂O
• mdl: MFCD12178270
• 分子量: 180.25
• InChiKey: XKBDLUQAHMKDTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Treatment Methods Employing Histamine H3 Receptor Antagonists, Including Betahistine
  申请人：Nelson Erik B.

  公开号：US20090298892A1

  公开（公告）日：2009-12-03

  Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount of a histamine type 3 (Bb) receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, or its metabolites to an individual.
• US8119668B2
  申请人：——

  公开号：US8119668B2

  公开（公告）日：2012-02-21
• US8242148B2
  申请人：——

  公开号：US8242148B2

  公开（公告）日：2012-08-14
• [EN] TREATMENT METHODS EMPLOYING HISTAMINE H3 RECEPTOR ANTAGONISTS, INCLUDING BETAHISTINE<br/>[FR] PROCEDES DE TRAITEMENT EMPLOYANT DES ANTAGONISTES D'HISTAMINE H3 Y COMPRIS DE LA BETAHISTINE
  申请人：UNIV CINCINNATI

  公开号：WO2007076140A2

  公开（公告）日：2007-07-05

  [EN] Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount of a histamine type 3 (Bb) receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, or its metabolites to an individual.
  [FR] La présente invention concerne des procédés de traitement de la dépression, des troubles de frénésie alimentaire, de la narcolepsie, de l'hypersomnie (EDS), des troubles d'abus de substance et du syndrome de Prader Willi, des troubles caractérisés au moins en partie par une hypocortisolémie et la réduction de l'activité de l'axe hypothalamo-hypophyso-surrénalien (HPA) et des troubles liées aux troubles du rythme circadien, y compris l'étape d'administration d'une quantité effective d'antagoniste de récepteur de type 3 (Bb), telle que la bétahistine ou ses sels pharmaceutiquement acceptables ou ses métabolites chez un individu.